← Eichor
Study identifier: NCT04373317 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

Condition: Parkinson's Disease Psychosis  ·  Sponsor: VA Office of Research and Development

PhasePhase 4
Planned participants358
Who can joinAll sexes, 40 Years to no upper limit
Healthy volunteersYes

About this study

Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions). Hallucinations or delusions, together called psychosis, occur in up to 60% of PD patients at some point in time. Parkinson's disease psychosis can sometimes be associated with decreased quality of life, increased nursing home placement, increased rate of death, and greater caregiver burden. There are approximately 50,000 Veterans with Parkinson's disease receiving care in the VA, and up to 30,000 (60%) of them will experience psychosis at some point in time. Quetiapine is an antipsychotic drug approved by the Food and Drug Administration (FDA) that is the most commonly used medication to treat PD psychosis, but more studies are needed to determine if it works for this condition and is also well tolerated and safe. Pimavanserin is a newer antipsychotic drug approved by the Food and Drug Administration (FDA) specifically to treat PD psychosis, but more studies are needed to determine if it works and its safety. The purpose of this research is to gather additional information on the safety and effectiveness of both Quetiapine and Pimavanserin. By doin…

This description comes directly from the study's public registry record.

Talk to the study team

Daniel Weintraub, MD  ·  (215) 823-5800  ·  daniel.weintraub@va.gov

John E Duda, MD  ·  (215) 823-5934  ·  john.duda@va.gov

Always discuss trial participation with your own doctor first.

Locations (24)

Southern Arizona VA Health Care System, Tucson, AZTucson, Arizona, United StatesTerminated
VA Loma Linda Healthcare System, Loma Linda, CALoma Linda, California, United StatesRecruiting
VA Palo Alto Health Care System, Palo Alto, CAPalo Alto, California, United StatesRecruiting
San Francisco VA Medical Center, San Francisco, CASan Francisco, California, United StatesActive Not Recruiting
VA Greater Los Angeles Healthcare System, West Los Angeles, CAWest Los Angeles, California, United StatesTerminated
Rocky Mountain Regional VA Medical Center, Aurora, COAurora, Colorado, United StatesRecruiting
North Florida/South Georgia Veterans Health System, Gainesville, FLGainesville, Florida, United StatesActive Not Recruiting
Edward Hines Jr. VA Hospital, Hines, ILHines, Illinois, United StatesActive Not Recruiting
Lexington VA Medical Center, Lexington, KYLexington, Kentucky, United StatesTerminated
VA Ann Arbor Healthcare System, Ann Arbor, MIAnn Arbor, Michigan, United StatesActive Not Recruiting
Minneapolis VA Health Care System, Minneapolis, MNMinneapolis, Minnesota, United StatesRecruiting
St. Louis VA Medical Center John Cochran Division, St. Louis, MOSt Louis, Missouri, United StatesActive Not Recruiting

+ 12 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04373317